Rogaine first year sales trending at over $100 mil. based on IRI data through November.
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE FIRST YEAR OTC SALES TRENDING AT OVER $100 MIL., according to data from Information Resources, Inc. Launched in April, the Rx-to-OTC switch product showed sales through November of $96.8 mil. in food, drug and mass merchandiser outlets, constituting an 86.8% dollar share of the hair regrowth market. Pharmacia & Upjohn has predicted that five-year OTC Rogaine sales will total $650 mil. ("The Tan Sheet" May 13, 1996, In Brief)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.